Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466566 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
A Phase 3 study of Healthy, sponsored by Adrian Vella.
- Completed
- Registry status
- Phase 3
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT04466566: Completed Phase 3 study of Healthy, sponsored by Adrian Vella.
NCT04466566 is a Phase 3 study of Healthy that has completed, run by Adrian Vella. The registered enrollment target is 21 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04466566, a Phase 3 study of Healthy, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study to find out how genetic variations in GLP1R alter insulin secretion, in the fasting state and when blood sugars levels are elevated.
Conditions Studied
Interventions
- OTHER Saline
- BIOLOGICAL Exendin-9,39
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 3 |
What the finished NCT04466566 record still lists
NCT04466566 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT04466566 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04466566 about?
NCT04466566 is a clinical study titled "A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics". The GLP-1 receptor (GLP1R) gene is found on the beta cells of the pancreas. Its role is in the control of blood sugar level by enhancing insulin secretion from the pancreas after eating a meal. The purpose of this research study to find out how genetic variations in GLP1R alter insulin secretion, in...
What is the current status of trial NCT04466566?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21 participants. The study started on 2022-10-17. Estimated completion is 2025-12-30.
What conditions does trial NCT04466566 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT04466566?
The interventions under investigation include: Saline (OTHER), Exendin-9,39 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04466566?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04466566 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04466566's enrollment target sits among peer trials
21 857th of 1090 higher than 231 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
RECRUITING · Phase 3
-
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
RECRUITING · Phase 3
-
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
COMPLETED · Phase 3
-
Study to Investigate the Potential of Probiotics in Yogurt
COMPLETED · Phase 3
-
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
COMPLETED · Phase 3
-
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI